Generic placeholder image

Current Cancer Therapy Reviews

Author(s): Besmir Hyseni, Ilir Mazreku and Kemajl Bislimi*

DOI: 10.2174/1573394719666221103094845

DownloadDownload PDF Flyer Cite As
The Role of Graphene Oxide in the Inhibition of Migration and Invasion of Cancer Cells by Destroying Actin Cytoskeleton and via Inhibiting the Activities of ETC Complexes

Page: [132 - 137] Pages: 6

  • * (Excluding Mailing and Handling)

Abstract

Cancer is one of the most important threats to public health. Cancer is characterized by cell proliferation that has eluded central endogenous control mechanisms. Cervical cancer is the third most common cancer among women, followed by skin cancer and breast cancer, the first and second most common causes, respectively. In developing countries, cervical cancer is usually the most common cancer in women and may account for 25% of all female cancers.

Over the years, the diagnosis and treatment of cervical cancer have made rapid progress, resulting in a decline in the mortality and morbidity of the disease. Unfortunately, although surgery and radiotherapy have effective treatment options for early cervical cancer, poor prognosis is still a challenge in the treatment of metastatic cervical cancer. Therefore, it is very important to reveal the mechanism of cervical cancer and explore new therapies against tumor invasiveness.

At present, it is reported that nanomaterials are used in the detection and treatment of various types of malignant tumors due to their different targeting effects in many fields, such as imaging, immune detection, chemotherapy, radiotherapy and immunotherapy.

The cytotoxicity and inhibitory effects of graphene oxide (GO) on tumor invasion and metastasis were studied in recent studies using the human cervical cancer Hela cell line, as well as the probable mechanisms and signaling pathways involved.

Here we collect the last reports, with focus on the role of GO in the inhibition of migration and invasion of cancer cells with the goal of exposing possible potential pathways to provide new insights for specific treatment of cancer.

Graphical Abstract

[1]
Carcio HA, Secor RM. Advanced health assessment of women. Advanced health assessment of women. Germany: Springer 2018.
[http://dx.doi.org/10.1891/9780826124623]
[2]
Li H, Wu X, Cheng X. Advances in diagnosis and treatment of metastatic cervical cancer. J Gynecol Oncol 2016; 27(4), e43.
[http://dx.doi.org/10.3802/jgo.2016.27.e43] [PMID: 27171673]
[3]
Marth C, Landoni F, Mahner S, McCormack M, Gonzalez MA, Colombo N. Cervical cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2017; 28 (Suppl. 4): iv72-83.
[http://dx.doi.org/10.1093/annonc/mdx220] [PMID: 28881916]
[4]
Vlček J, Lapčík L, Havrdová M, et al. Flow induced hela cell detachment kinetics show that oxygen-containing functional groups in graphene oxide are potent cell adhesion enhancers. Nanoscale 2019; 11(7): 3222-8.
[http://dx.doi.org/10.1039/C8NR08994A] [PMID: 30706925]
[5]
Wang J, Wang P, He Y, et al. Graphene oxide inhibits cell migration and invasion by destroying actin cytoskeleton in cervical cancer cells. Aging 2020; 12(17): 17625-33.
[http://dx.doi.org/10.18632/aging.103821] [PMID: 32924971]
[6]
Ryabchikova E. Advances in nanomaterials in biomedicine. Nanomaterials 2021; 11(1): 118.
[http://dx.doi.org/10.3390/nano11010118]
[7]
Qin W, Huang G, Chen Z, Zhang Y. Nanomaterials in targeting cancer stem cells for cancer therapy. Front Pharmacol 2017; 8: 1.
[http://dx.doi.org/10.3389/fphar.2017.00001]
[8]
Findik F. Nanomaterials and their Applications. Period Eng Nat Sci 2021; 9(3): 62-75.
[http://dx.doi.org/10.21533/pen.v9i3.1837]
[9]
Dideikin AT, Vul’ AY. Graphene oxide and derivatives: The place in graphene family. Front Phys 2019; 6: 149.
[http://dx.doi.org/10.3389/fphy.2018.00149]
[10]
Dimiev AM, Eigler S. Graphene oxide: Fundamentals and applications graphene oxide: Fundamentals and applications. New Jersey: Wiley 2016.
[11]
Wu SY, An SSA, Hulme J. Current applications of graphene oxide in nanomedicine. Int J Nanomed 2015; 10: 9-24.
[12]
Priyadarsini S, Mohanty S, Mukherjee S, Basu S, Mishra M. Graphene and graphene oxide as nanomaterials for medicine and biology application. J Nanostructure Chem 2018; 8(2): 123-37.
[http://dx.doi.org/10.1007/s40097-018-0265-6]
[13]
Zhou H, Zhang B, Zheng J, et al. The inhibition of migration and invasion of cancer cells by graphene via the impairment of mitochondrial respiration. Biomaterials 2014; 35(5): 1597-607.
[http://dx.doi.org/10.1016/j.biomaterials.2013.11.020] [PMID: 24290441]
[14]
Szmidt M, Stankiewicz A, Urbańska K, et al. Graphene oxide down-regulates genes of the oxidative phosphorylation complexes in a glioblastoma. BMC Mol Biol 2019; 20(1): 2.
[http://dx.doi.org/10.1186/s12867-018-0119-2] [PMID: 30602369]
[15]
Das SS, Alkahtani S, Bharadwaj P, Ansari MT. Molecular insights and novel approaches for targeting tumor metastasis. Int J Pharm 2020; 585, 119556.
[16]
Klementieva NV, Snopova LB, Prodanets NN, et al. Fluorescence imaging of actin fine structure in tumor tissues using sir-actin staining. Anticancer Res 2016; 36(10): 5287-94.
[17]
Stehn JR, Haass NK, Bonello T, et al. A novel class of anticancer compounds targets the actin cytoskeleton in tumor cells. Cancer Res 2013; 73(16): 5169-82.
[http://dx.doi.org/10.1158/0008-5472.CAN-12-4501] [PMID: 23946473]
[18]
Yang Y, Zheng H, Zhan Y, Fan S. An emerging tumor invasion mechanism about the collective cell migration. Am J Transl Res 2019; 11(9): 5301-12.
[19]
Chakrabarti R, Lee M, Higgs HN. Multiple roles for actin in secretory and endocytic pathways. Curr Biol 2021; 31(10): R603-18.
[http://dx.doi.org/10.1016/j.cub.2021.03.038] [PMID: 34033793]
[20]
Desouza M, Gunning PW, Stehn JR. The actin cytoskeleton as a sensor and mediator of apoptosis. Bioarchitecture 2012; 2(3): 75-87.
[http://dx.doi.org/10.4161/bioa.20975] [PMID: 22880146]
[21]
Schaks M, Giannone G, Rottner K. Actin dynamics in cell migration. Essays Biochem 2019; 63(5): 483-95.
[http://dx.doi.org/10.1042/EBC20190015] [PMID: 31551324]
[22]
Tian X, Yang Z, Duan G, et al. Graphene oxide nanosheets retard cellular migration via disruption of actin cytoskeleton. Small 2017; 13(3), 1602133.
[http://dx.doi.org/10.1002/smll.201602133] [PMID: 27762498]
[23]
Yu Q, Zhang B, Li J, Li M. The design of peptide-grafted graphene oxide targeting the actin cytoskeleton for efficient cancer therapy. Chem Commun 2017; 53(83): 11433-6.
[http://dx.doi.org/10.1039/C7CC06537J] [PMID: 28975935]
[24]
Wu J, Yang R, Zhang L, Fan Z, Liu S. Cytotoxicity effect of graphene oxide on human MDA-MB-231 cells. Toxicol Mech Methods 2015; 25(4): 312-9.
[http://dx.doi.org/10.3109/15376516.2015.1031415] [PMID: 25996036]
[25]
Duan G, Zhang Y, Luan B, et al. Graphene-induced pore formation on cell membranes. Sci Rep 2017; 7(1): 42767.
[http://dx.doi.org/10.1038/srep42767] [PMID: 28218295]
[26]
Tabish TA, Pranjol MZI, Jabeen F, et al. Investigation into the toxic effects of graphene nanopores on lung cancer cells and biological tissues. Appl Mater Today 2018; 12: 389-401.
[http://dx.doi.org/10.1016/j.apmt.2018.07.005]
[27]
Krętowski R, Jabłońska TA, Cechowska PM. The preliminary study on the proapoptotic effect of reduced graphene oxide in breast cancer cell lines. Int J Mol Sci 2021; 22(22): 12593.
[http://dx.doi.org/10.3390/ijms222212593] [PMID: 34830472]
[28]
Svitkina TM. Actin cell cortex: Structure and molecular organization. Trends Cell Biol 2020; 30(7): 556-65.
[http://dx.doi.org/10.1016/j.tcb.2020.03.005] [PMID: 32278656]
[29]
Ghorbani M, Soleymani H, Hashemzadeh H, et al. Microfluidic investigation of the effect of graphene oxide on mechanical properties of cell and actin cytoskeleton networks: Experimental and theoretical approaches. Sci Rep 2021; 11(1): 16216.
[http://dx.doi.org/10.1038/s41598-021-95624-0] [PMID: 34376720]
[30]
Zhang W, Wang F, Hu C, Zhou Y, Gao H, Hu J. The progress and perspective of nanoparticle-enabled tumor metastasis treatment. Acta Pharm Sin B 2020; 10(11): 2037-53.
[31]
Avouris P, Dimitrakopoulos C. Graphene: Synthesis and applications. Mater Today 2012; 15(3): 86-97.
[http://dx.doi.org/10.1016/S1369-7021(12)70044-5]
[32]
Liu L, Ma Q, Cao J, et al. Recent progress of graphene oxide-based multifunctional nanomaterials for cancer treatment. Cancer Nanotechnol 2021; 12: 8.
[33]
Sharma H, Mondal S. Functionalized graphene oxide for chemotherapeutic drug delivery and cancer treatment: A promising material in nanomedicine. Int J Mol Sci 2020; 21(17): 6280.
[http://dx.doi.org/10.3390/ijms21176280] [PMID: 32872646]
[34]
He Y, Jiao B, Tang H. Interaction of single-stranded DNA with graphene oxide: Fluorescence study and its application for S1 nuclease detection. RSC Advances 2014; 4(35): 18294-300.
[http://dx.doi.org/10.1039/C4RA01102C]
[35]
Szczepaniak J, Jagiello J, Wierzbicki M, et al. Article reduced graphene oxides modulate the expression of cell receptors and voltage-dependent ion channel genes of glioblastoma multiforme. Int J Mol Sci 2021; 22(2): 515.
[http://dx.doi.org/10.3390/ijms22020515] [PMID: 33419226]
[36]
Lloyd RE, Keatley K, Littlewood DTJ, et al. Identification and functional prediction of mitochondrial complex III and IV mutations associated with glioblastoma. Neuro Oncol 2015; 17(7): 942-52.
[http://dx.doi.org/10.1093/neuonc/nov020] [PMID: 25731774]
[37]
Griguer CE, Cantor AB, Fathallah SHM, et al. Prognostic relevance of cytochrome C oxidase in primary glioblastoma multiforme. PLoS One 2013; 8(4), e61035.
[http://dx.doi.org/10.1371/journal.pone.0061035] [PMID: 23593382]
[38]
Suzuki C, Daigo Y, Kikuchi T, Katagiri T, Nakamura Y. Identification of COX17 as a therapeutic target for non-small cell lung cancer. Cancer Res 2003; 63(21): 7038-41.
[PMID: 14612491]
[39]
Herrera GNE, Fernández RF, Martínez PE, Carrillo RJD, Herrera GNE. Molecular analysis by gene expression of mitochondrial ATPase subunits in papillary thyroid cancer: Is ATP5E transcript a possible early tumor marker? Med Sci Monit 2015; 21: 1745-51.
[http://dx.doi.org/10.12659/MSM.893597] [PMID: 26079849]
[40]
Guo W, Chen Z, Feng X, et al. Graphene Oxide (GO)-based nanosheets with combined chemo/photothermal/photodynamic therapy to overcome Gastric Cancer (GC) paclitaxel resistance by reducing mitochondria-derived Adenosine-Triphosphate (ATP). J Nanobiotechnol 2021; 19(1): 146.
[http://dx.doi.org/10.1186/s12951-021-00874-9] [PMID: 34011375]
[41]
Phan LM, Yeung SCJ, Lee MH. Cancer metabolic reprogramming: Importance, main features, and potentials for precise targeted anticancer therapies. Cancer Biol Med 2014; 11(1): 1-19.
[PMID: 24738035]
[42]
Lu J. The Warburg metabolism fuels tumor metastasis. Cancer Metastasis Rev 2019; 38(1-2): 157-64.
[http://dx.doi.org/10.1007/s10555-019-09794-5]
[43]
Fiorillo M, Ózsvári B, Sotgia F, Lisanti MP. High ATP production fuels cancer drug resistance and metastasis: Implications for mitochondrial ATP depletion therapy. Front Oncol 2021; 11, 740720.
[http://dx.doi.org/10.3389/fonc.2021.740720] [PMID: 34722292]